Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3539)	8/4/1999 8:51:00 PM
From: BMcV	Read Replies (1) \| Respond to of 10280

>>If I was SEPR, I would gobble up CELG.<< Please, not now. That would be good for another 5 points down.

To: Biomaven who wrote (3539)	8/6/1999 1:34:00 PM
From: j_fir2	Read Replies (1) \| Respond to of 10280

Hmm. Well, considering I was asking Jonae about pairs of drugs on the market (parent and "child") it's curious that she mentioned thalmidomide at all (if in this case the original drug is simply being brought to the market for another indication). That happens all the time, seems to me. She did maintain that SEPR has passed on the patent for the single isomer version--I guess you've explained why, Peter. Maybe she had Celgene on her mind for other reasons? We didn't discuss the stock price but she also said 'There is a lot going on." Well, we know that. I'm comfortable waiting for the next event from these scientists and businessmen.